At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.
Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications such as diabetes.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
Gilead has made it a priority to help ensure worldwide access to its first-in-class treatment for hepatitis C, Sovaldi. Learn more.
Access earnings press release, webcast link and slides for Gilead’s first quarter 2014 results. View materials.
April 22, 2014 Gilead Sciences Announces First Quarter 2014 Financial Results